Literature DB >> 15896242

Cost considerations of the new fixed combinations for glaucoma medical therapy.

M P Ventura1, N E Saheb, H P Solari, V S Saraiva, R N G Vianna, M N Burnier.   

Abstract

OBJECTIVE: To compare the costs of the new fixed combinations for glaucoma medical therapy.
METHODS: The studied drugs were: Cosopt (5-mL bottle), Combigan (5-mL bottle) and Xalacom (2.5-mL bottle). Five bottles of each drug were obtained from pharmacies, and the medications lot numbers were recorded. To calculate the drop volume, 10 drops and 1 mL of each bottle were weighed with a digital precision scale. Drop volume was calculated by the relation between volume and weight. The cost of each bottle of medication was determined from the average retail price in Canada. The prices were obtained in Canadian dollars (dollars).
RESULTS: The drops of Cosopt (39.60 +/- 0.45 microL) were considerably larger than the drops of Combigan (33.75 +/- 0.60 microL) and Xalacom (30.87 +/- 0.37 microL). The average number of drops per millilitre varied from 25.25 +/- 0.29 (Cosopt) to 32.40 +/- 0.39 microL (Xalacom). Combigan presented the lowest daily cost (dollars 0.87 +/- 0.02) followed by Xalacom (dollars 1.09 +/- 0.01) and Cosopt (dollars 1.22 +/- 0.01). The average cost by year varied from dollars 316.75 +/- 5.59 (Combigan) to dollars 445.96 +/- 5.16 (Cosopt), with a total difference of dollars 129.21 per year of treatment.
CONCLUSIONS: There was a statistically significant difference in average drop size and cost among the three studied drugs. Combigan presented the lowest daily cost followed by Xalacom and Cosopt.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15896242     DOI: 10.1111/j.1365-2710.2005.00641.x

Source DB:  PubMed          Journal:  J Clin Pharm Ther        ISSN: 0269-4727            Impact factor:   2.512


  4 in total

Review 1.  Topical brimonidine 0.2%/timolol 0.5% ophthalmic solution: in glaucoma and ocular hypertension.

Authors:  James E Frampton
Journal:  Drugs Aging       Date:  2006       Impact factor: 3.923

2.  Daily Costs and Cost Effectiveness of Glaucoma Fixed Combinations in China.

Authors:  Chenjia Xu; Ruru Guo; Dandan Huang; Jian Ji; Wei Liu
Journal:  J Ophthalmol       Date:  2020-07-30       Impact factor: 1.909

3.  Rational use of the fixed combination of dorzolamide - timolol in the management of raised intraocular pressure and glaucoma.

Authors:  Jason Yeh; Daniel Kravitz; Brian Francis
Journal:  Clin Ophthalmol       Date:  2008-06

4.  Comparison between bimatoprost and latanoprost-timolol fixed combination for efficacy and safety after switching patients from latanoprost.

Authors:  Yuko Maruyama; Yoko Ikeda; Kazuhiko Mori; Morio Ueno; Haruna Yoshikawa; Shigeru Kinoshita
Journal:  Clin Ophthalmol       Date:  2015-08-07
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.